IMPORTANCE: The @entity7093 / @entity7094 fusion transcript, which arises from the @entity7093 / @entity7094 translocation, is a molecular marker unique to @entity3975 ( @entity3975 ), the most common @entity5 of the salivary gland. The extent to which the transcript influences disease features and @entity1 survival is unclear. OBJECTIVE: To determine whether the @entity7093 / @entity7094 fusion transcript is associated with disease stage, @entity5 grade, or survival outcomes in @entity1 with @entity3975 . DESIGN, SETTING, AND @entity1 : A retrospective medical record review was performed at a tertiary-care academic medical institution. The review included 90 @entity1 with @entity3975 who underwent treatment from January 1, 1995, to December 31, 2011, and for whom archived @entity406 -fixed, @entity982 -embedded @entity5 specimens were available. Records were reviewed for clinical, demographic, and survival data. Tumor specimens underwent fluorescence in situ hybridization. Follow-up was completed on May 15, 2014, and data were analyzed from June 1 to July 1, 2014. MAIN OUTCOMES AND MEASURES: @entity7093 / @entity7094 fusion transcript status. Statistical analysis determined whether transcript status was associated with disease stage, @entity5 grade, and/or overall and disease-free survival. RESULTS: Among the 90 eligible @entity1 (median [range] age, 55.1 [7.8-89.2] years), 42 were female and 48 were male. Fluorescence in situ hybridization revealed a @entity7093 / @entity7094 translocation in 50 @entity1 (56%). The translocations were more prevalent in intermediate-grade @entity5 (31 of 49 [63%]) than in high-grade (11 of 49 [22%]) and low-grade (7 of 49 [14%]) @entity5 ; 1 @entity5 sample had no available grading. Similar proportions of @entity1 with translocation-positive disease had T1 (13 of 49 [26%]), T2 (15 of 49 [31%]), @entity6461 (14 of 49 [28%]), or T0 or Tx (8 of 49 [16%]) stages of disease. Thirty-eight of 49 @entity1 with translocation-positive @entity3975 (78%) had N0 stage of disease. Rates of 5-year overall survival were similar for @entity1 with translocation-positive and translocation-negative disease (76.8% vs 75.5%, respectively; P   =   .17), as were rates of disease-free survival (65.2% vs 57.4%, respectively; P   =   .28). CONCLUSIONS AND RELEVANCE: Detection of the @entity7093 / @entity7094 fusion transcript provides useful information for @entity3975 diagnosis but is not associated with differences in survival outcomes.

Role of @entity7093 / @entity7094 Translocation in the Prognosis and Clinical Outcomes of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PARTICIPANTS'] @entity6461 :: ('6317', 'Gene') :: ['T4a'] @entity7094 :: ('84441', 'Gene') :: ['MAML2'] @entity3975 :: ('MESH:D018277', 'Disease') :: ['mucoepidermoid carcinoma', 'MEC'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'malignant tumor', 'tumors'] @entity7093 :: ('23373', 'Gene') :: ['CRTC1'] @entity406 :: ('MESH:D005557', 'Chemical') :: ['formalin'] @entity982 :: ('MESH:D010232', 'Chemical') :: ['paraffin']
@entity3975 :: (MESH:D018277,Disease) :: ['Mucoepidermoid Carcinoma']
